The Drug Enforcement Administration announced this week that it plans to classify 7-hydroxymitragynine — a psychoactive compound derived from the kratom plant — as Schedule I, placing it alongside heroin and LSD as a substance with no accepted medical use. Three related synthetic compounds would receive the same designation. According to The Hill, the ban is temporary, but temporary DEA emergency scheduling has a way of becoming permanent. The agency has done this before.
What the DEA announcement does not address — and what no federal agency has been asked to explain — is why the United States remains in the grip of an opioid crisis that pharmaceutical manufacturers and distributors built, profited from, and largely survived. OxyContin is still on the market. Purdue Pharma's successors are still operating. The consulting firms that helped opioid companies maximize prescriptions paid fines and moved on. The industry that addicted millions of Americans to synthetic opioids is not scheduled. It is regulated, subsidized, and in some cases, actively expanded.
That context is not incidental to the kratom ban. It is the entire story.
7-OH is a compound found in small amounts in the kratom plant (Mitragyna speciosa), a Southeast Asian tree used for centuries in traditional medicine. Since then, manufacturers have synthesized and concentrated 7-OH into commercially sold products — tinctures, capsules, shots — marketed for pain relief and opioid withdrawal support. The DEA's proposed ban targets these synthetic, concentrated forms, not kratom leaf itself, though advocates warn the distinction may not hold in enforcement.
Kratom occupies a strange position in American drug policy. The plant itself — a Southeast Asian tree with a centuries-long history of traditional use — has been used by hundreds of thousands of Americans, many of them managing chronic pain, opioid withdrawal, or anxiety without a prescription and without the involvement of a pharmaceutical company. The DEA tried to ban kratom outright in 2016. A public backlash involving patient advocates, veterans groups, and members of Congress forced the agency to withdraw the proposal. This new action targets the synthetic, concentrated versions of 7-OH specifically, but kratom advocates have long argued that any federal action against the compound's derivatives is a step toward eliminating the plant-based alternative entirely.
The DEA's stated rationale is safety. Concentrated 7-OH products have been linked to adverse events, including overdose deaths when combined with other substances. That concern is not fabricated. But the agency's threshold for action depends enormously on who is selling the dangerous product. Prescription opioids — fentanyl, oxycodone, hydrocodone — are Schedule II: dangerous, tightly controlled, but legal. They killed more than 80,000 Americans in 2021 alone, according to the Centers for Disease Control and Prevention. The pharmaceutical supply chain that manufactured and distributed them has faced civil settlements but no Schedule I reclassification, no emergency ban, no removal from the market.
The asymmetry is not a regulatory anomaly. It is the operating logic of American drug policy, and it runs on money.
The pharmaceutical industry spent more than $370 million lobbying Congress between 2019 and 2023, according to data compiled by OpenSecrets. That figure does not include political action committee contributions, which have flowed to members of both parties on committees that oversee drug regulation. The kratom industry — a collection of small businesses, online retailers, and herbal supplement companies — has no comparable infrastructure. It has no PAC. It has no revolving door with the FDA or DEA. What it has is a customer base that is, in many cases, composed of exactly the people the opioid industry broke: chronic pain patients who were prescribed opioids, became dependent, lost access when prescribing guidelines tightened, and found that kratom helped them function without returning to the pharmaceutical supply chain.
This is the population the DEA's action will most directly affect. Not recreational drug users seeking a high — though some kratom users fall into that category — but people managing real, documented conditions who turned to an unpatented plant after the patented pharmaceuticals either failed them or were taken away. Their experience does not appear in the DEA's scheduling announcement. It rarely does.
The drug war has always been better at targeting the alternatives than the sources. As Tinsel News has previously reported, prohibition does not eliminate demand — it redirects it toward less regulated, often more dangerous substitutes. When the DEA banned kratom's predecessor compounds in earlier scheduling actions, manufacturers responded by isolating and concentrating different alkaloids. When state legislatures banned specific synthetic cannabinoids, chemists modified the molecular structure and sold the new compound legally for months before regulators caught up. Scheduling 7-OH will not reduce demand for opioid-adjacent pain relief. It will redirect users toward substances with less research, less community knowledge, and less predictable risk profiles.
The marijuana rescheduling debate offers an instructive parallel. As Tinsel News noted in coverage of that process, rescheduling decisions have consistently served pharmaceutical and political interests over public health ones — moving substances up or down the schedule based on patent potential and lobbying pressure rather than evidence of harm relative to legal alternatives. Kratom has no patent. No pharmaceutical company profits from its sale. That fact alone tells you something about why it is being scheduled rather than studied.
The DEA frames its action as consumer protection. But consumer protection, applied consistently, would require the agency to explain why concentrated synthetic opioids manufactured by Fortune 500 companies — products that have killed hundreds of thousands of Americans — remain Schedule II while a plant compound used primarily by people managing withdrawal and chronic pain gets emergency Schedule I status. The agency has not offered that explanation. It is not required to.
What the ban will do, concretely: people currently using 7-OH products to manage opioid withdrawal will lose access to a tool that, for some of them, is the only thing standing between sobriety and relapse. Some will return to prescription opioids. Some will return to heroin or illicit fentanyl. Some will find another unregulated compound. The pharmaceutical industry will experience no disruption. Its products will remain on pharmacy shelves, covered by insurance, prescribed by doctors, and marketed to the same population that kratom was serving.
The DEA's announcement is not a public health intervention. It is a maintenance action — keeping the unpatented, unlobbyable alternative out of the market while leaving the infrastructure of pharmaceutical addiction exactly where it is. The people who will pay for that distinction are the ones who can least afford to.
